<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214109</url>
  </required_header>
  <id_info>
    <org_study_id>248.665</org_study_id>
    <nct_id>NCT01214109</nct_id>
  </id_info>
  <brief_title>Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers</brief_title>
  <official_title>A Multiple Dose Bioequivalence Study of Pramipexole With Increasing Doses (0.375mg to 1.5mg q.d.) of Oral Extended Release (ER) Tablet in Two-way Cross-over Comparison of 0.375mg Extended Release Tablet q.d. Versus 0.125mg Immediate Release (IR) Tablet t.i.d and 1.5 mg Extended Release Tablet q.d. Versus 0.5mg Immediate Release Tablet t.i.d. in Chinese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To establish bioequivalence at steady state of:

      1)0.375 mg pramipexole extended release tablet q.d. in fasted status versus 0.125 mg
      pramipexole Immediate release tablet t.i.d. in fasted status 2)1.5 mg pramipexole extended
      release tablet q.d. in fasted status versus 0.5 mg pramipexole Immediate release tablet
      t.i.d. in fasted status

      To investigate dose proportionality of pharmacokinetics parameters for:

      1)pramipexole extended release dosage of 0.375 to 1.5 mg q.d.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for Pharmacokinetic (PK) Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Steady State Concentration (Cmax,ss) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>Cmax = maximum observed concentration of the analyte in plasma at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Steady State Concentration (Cmax,ss) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>Cmax,ss = maximum observed concentration of the analyte in plasma at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>tmax = time of maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>tmax = time of maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-to-trough Fluctuation (PTF) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>PTF = Peak-to-trough fluctuation is measured as a percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-to-trough Fluctuation (PTF) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>PTF = Peak-to-trough fluctuation is measured as a percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>Cavg = Average concentration of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>Cavg = Average concentration of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>t1/2,ss - Apparent plasma terminal elimination half-life at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>t1/2,ss - Apparent plasma terminal elimination half-life at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Steady State Concentration (Cmin,ss) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Steady State Concentration (Cmin,ss) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (All Subjects)</measure>
    <time_frame>27 days</time_frame>
    <description>Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (Excluding Subjects Due to Emesis)</measure>
    <time_frame>27 days</time_frame>
    <description>Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>pramipexole extended release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pramipexole immediate release</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole extended release</intervention_name>
    <description>0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)</description>
    <arm_group_label>pramipexole immediate release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole extended release</intervention_name>
    <description>0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)</description>
    <arm_group_label>pramipexole extended release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole immediate release</intervention_name>
    <description>0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)</description>
    <arm_group_label>pramipexole immediate release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole immediate release</intervention_name>
    <description>0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)</description>
    <arm_group_label>pramipexole extended release</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure, pulse rate), 12-lead electrocardiogram, clinical laboratory tests

          2. Age older than or equal 18 and Age younger than or equal 40 years

          3. Body Mass Index larger than or equal 19 and Body Mass Index less than or equal 24kg/m2

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation.

        Exclusion criteria:

          1. Any finding of the medical examination (including Pulse Rate and electrocardiogram)
             deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          9. Intake of drugs with a long half-life (longer than 24 hours) within at least one month
             or less than 10 half-lives of the respective drug prior to administration or during
             the trial

         10. Use of drugs which might reasonably influence the results of the trial up to 7 days
             before the start of drug administration in the study or during the study period

         11. Participation in another trial with an investigational drug within one months prior to
             administration or during the trial

         12. Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day)

         13. Inability to refrain from smoking on trial days

         14. Alcohol abuse (more than 40 g/day)

         15. Drug abuse

         16. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         17. Excessive physical activities (within one week prior to administration or during the
             trial)

         18. Any laboratory value outside the reference range that is of clinical relevance

         19. Any positive results in hepatitis B surface antigen (HBsAg), anti hepatitis B core
             (HBc) antibodies, anti hepatitis C virus (HCV) antibodies and human immunodeficiency
             virus (HIV) test

             Exclusion criteria specific for this study:

         20. Hypersensitivity to pramipexole or other dopamine agonists

         21. Supine blood pressure at screening of systolic&lt;100 mmHg and diastolic &lt; 60 mmHg, or
             symptomatic orthostatic hypotension (i. .e. clinical symptoms of orthostatic
             hypotension associated with a decline &gt;=20 mmHg in systolic BP and a decline &gt;=10 mmHg
             in diastolic BP, at one minute after standing compared to the previous supine systolic
             and diastolic BP obtained after 5 minutes of quiet rest)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.665.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <results_first_submitted>January 25, 2012</results_first_submitted>
  <results_first_submitted_qc>January 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2012</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>24 subjects were equally randomised to one of two groups / sequences, and in general terms, ABCD or BADC. Hence, 12 subjects were in group ABCD and 12 in BADC. All 24 subjects received all treatments, A, B, C, D. The numbers presented in the milestone are by overall treatment, A, B, C or D.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.375 mg q.d.Extended Release (ER)</title>
          <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
        </group>
        <group group_id="P2">
          <title>0.125 mg t.i.d. Immediate Release (IR)</title>
          <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
        </group>
        <group group_id="P3">
          <title>1.5 mg q.d. ER</title>
          <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
        </group>
        <group group_id="P4">
          <title>0.5 mg t.i.d. IR</title>
          <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>24 subjects were equally randomised to one of two groups / sequences, and in general terms, ABCD or BADC. Hence, 12 subjects were in group ABCD and 12 in BADC. All 24 subjects received all treatments, A, B, C, D. The numbers presented are by overall treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for Pharmacokinetic (PK) Population (All Subjects)</title>
        <description>AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK population - Subjects with values for AUC0-24,ss for IR and values for AUCtau,ss for ER</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for Pharmacokinetic (PK) Population (All Subjects)</title>
          <description>AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state</description>
          <population>PK population - Subjects with values for AUC0-24,ss for IR and values for AUCtau,ss for ER</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.20" spread="29.7"/>
                    <measurement group_id="O2" value="7.50" spread="21.5"/>
                    <measurement group_id="O3" value="19.1" spread="113"/>
                    <measurement group_id="O4" value="20.4" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0.125 mg t.i.d. IR is the reference treatment, 0.375 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>82.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>74.45</ci_lower_limit>
            <ci_upper_limit>91.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>0.5 mg t.i.d. IR is the reference treatment, 1.5 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>96.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>69.33</ci_lower_limit>
            <ci_upper_limit>133.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK population excluding subjects with reported emesis - Subjects with values for AUC0-24,ss for IR and values for AUCtau,ss for ER, excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state</description>
          <population>PK population excluding subjects with reported emesis - Subjects with values for AUC0-24,ss for IR and values for AUCtau,ss for ER, excluding subjects with reported emesis</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="19.6"/>
                    <measurement group_id="O2" value="7.44" spread="22.6"/>
                    <measurement group_id="O3" value="24.8" spread="34.6"/>
                    <measurement group_id="O4" value="27.4" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0.125 mg t.i.d. IR vs. 0.375 mg q.d. ER 0.125 mg t.i.d. IR is the reference treatment, 0.375 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>88.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>80.76</ci_lower_limit>
            <ci_upper_limit>95.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>0.5 mg t.i.d. IR vs. 1.5 mg q.d. ER 0.5 mg t.i.d. IR is the reference treatment, 1.5 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>89.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>81.16</ci_lower_limit>
            <ci_upper_limit>98.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Steady State Concentration (Cmax,ss) for PK Population (All Subjects)</title>
        <description>Cmax = maximum observed concentration of the analyte in plasma at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK population - Subjects with values for Cmax,ss</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Steady State Concentration (Cmax,ss) for PK Population (All Subjects)</title>
          <description>Cmax = maximum observed concentration of the analyte in plasma at steady state</description>
          <population>PK population - Subjects with values for Cmax,ss</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.416" spread="25.3"/>
                    <measurement group_id="O2" value="0.469" spread="22.1"/>
                    <measurement group_id="O3" value="1.10" spread="130"/>
                    <measurement group_id="O4" value="1.20" spread="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0.125 mg t.i.d. IR vs. 0.375 mg q.d. ER 0.125 mg t.i.d. IR is the reference treatment, 0.375 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>88.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>79.89</ci_lower_limit>
            <ci_upper_limit>98.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>0.5 mg t.i.d. IR vs. 1.5 mg q.d. ER 0.5 mg t.i.d. IR is the reference treatment, 1.5 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>91.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>60.07</ci_lower_limit>
            <ci_upper_limit>140.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Steady State Concentration (Cmax,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>Cmax,ss = maximum observed concentration of the analyte in plasma at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK population excluding subjects with reported emesis - Subjects with values for Cmax,ss excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Steady State Concentration (Cmax,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>Cmax,ss = maximum observed concentration of the analyte in plasma at steady state</description>
          <population>PK population excluding subjects with reported emesis - Subjects with values for Cmax,ss excluding subjects with reported emesis</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.436" spread="20.6"/>
                    <measurement group_id="O2" value="0.463" spread="22.8"/>
                    <measurement group_id="O3" value="1.56" spread="26.5"/>
                    <measurement group_id="O4" value="1.61" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>0.125 mg t.i.d. IR is the reference treatment, 0.375 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>92.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>83.8</ci_lower_limit>
            <ci_upper_limit>102.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>0.5 mg t.i.d. IR is the reference treatment, 1.5 mg q.d. ER is the test treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>95.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>84.88</ci_lower_limit>
            <ci_upper_limit>106.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (All Subjects)</title>
        <description>tmax = time of maximum observed plasma concentration</description>
        <time_frame>27 days</time_frame>
        <population>PK population - Subjects with values for tmax</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (All Subjects)</title>
          <description>tmax = time of maximum observed plasma concentration</description>
          <population>PK population - Subjects with values for tmax</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.00" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>tmax = time of maximum observed plasma concentration</description>
        <time_frame>27 days</time_frame>
        <population>PK population excluding subjects with reported emesis - Subjects with values for t_max excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>tmax = time of maximum observed plasma concentration</description>
          <population>PK population excluding subjects with reported emesis - Subjects with values for t_max excluding subjects with reported emesis</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak-to-trough Fluctuation (PTF) for PK Population (All Subjects)</title>
        <description>PTF = Peak-to-trough fluctuation is measured as a percent</description>
        <time_frame>27 days</time_frame>
        <population>PK population - Subjects with values for PTF</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Peak-to-trough Fluctuation (PTF) for PK Population (All Subjects)</title>
          <description>PTF = Peak-to-trough fluctuation is measured as a percent</description>
          <population>PK population - Subjects with values for PTF</population>
          <units>percent</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="29.4"/>
                    <measurement group_id="O2" value="86.6" spread="27.5"/>
                    <measurement group_id="O3" value="101" spread="33.8"/>
                    <measurement group_id="O4" value="78.2" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak-to-trough Fluctuation (PTF) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>PTF = Peak-to-trough fluctuation is measured as a percent</description>
        <time_frame>27 days</time_frame>
        <population>PK population excluding subjects with reported emesis - Subjects with values for PTF excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Peak-to-trough Fluctuation (PTF) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>PTF = Peak-to-trough fluctuation is measured as a percent</description>
          <population>PK population excluding subjects with reported emesis - Subjects with values for PTF excluding subjects with reported emesis</population>
          <units>percent</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="28.9"/>
                    <measurement group_id="O2" value="86.2" spread="29.1"/>
                    <measurement group_id="O3" value="103" spread="28.3"/>
                    <measurement group_id="O4" value="82.5" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (All Subjects)</title>
        <description>Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose</description>
        <time_frame>27 days</time_frame>
        <population>PK population - Subjects with values for Cpre,ss</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (All Subjects)</title>
          <description>Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose</description>
          <population>PK population - Subjects with values for Cpre,ss</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculated</measurement>
                    <measurement group_id="O2" value="NA">Not calculated</measurement>
                    <measurement group_id="O3" value="NA">Not calculated</measurement>
                    <measurement group_id="O4" value="0.507" spread="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose</description>
        <time_frame>27 days</time_frame>
        <population>PK population excluding subjects with reported emesis - Subjects with values for Cpre,ss excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose</description>
          <population>PK population excluding subjects with reported emesis - Subjects with values for Cpre,ss excluding subjects with reported emesis</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Pharmacokinetic parameters which could not be determined were identified by “not calculated (NC)”.</measurement>
                    <measurement group_id="O2" value="NA">Pharmacokinetic parameters which could not be determined were identified by “not calculated (NC)”.</measurement>
                    <measurement group_id="O3" value="0.487" spread="105"/>
                    <measurement group_id="O4" value="0.616" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (All Subjects)</title>
        <description>Cavg = Average concentration of the analyte in plasma at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK Population - Subjects with values for Cavg</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (All Subjects)</title>
          <description>Cavg = Average concentration of the analyte in plasma at steady state</description>
          <population>PK Population - Subjects with values for Cavg</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.259" spread="29.7"/>
                    <measurement group_id="O2" value="0.312" spread="21.5"/>
                    <measurement group_id="O3" value="0.796" spread="113"/>
                    <measurement group_id="O4" value="0.848" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>Cavg = Average concentration of the analyte in plasma at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK Population excluding subjects with reported emesis - Subjects with values for Cavg excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>Cavg = Average concentration of the analyte in plasma at steady state</description>
          <population>PK Population excluding subjects with reported emesis - Subjects with values for Cavg excluding subjects with reported emesis</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.277" spread="19.6"/>
                    <measurement group_id="O2" value="0.310" spread="22.6"/>
                    <measurement group_id="O3" value="1.04" spread="34.6"/>
                    <measurement group_id="O4" value="1.14" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (All Subjects)</title>
        <description>t1/2,ss - Apparent plasma terminal elimination half-life at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK Population - Subjects with values for t1/2,ss</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (All Subjects)</title>
          <description>t1/2,ss - Apparent plasma terminal elimination half-life at steady state</description>
          <population>PK Population - Subjects with values for t1/2,ss</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="40.7"/>
                    <measurement group_id="O2" value="7.69" spread="28.6"/>
                    <measurement group_id="O3" value="14.4" spread="42.8"/>
                    <measurement group_id="O4" value="8.43" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>t1/2,ss - Apparent plasma terminal elimination half-life at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK Population excluding subjects with reported emesis - Subjects with values for t1/2,ss excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>t1/2,ss - Apparent plasma terminal elimination half-life at steady state</description>
          <population>PK Population excluding subjects with reported emesis - Subjects with values for t1/2,ss excluding subjects with reported emesis</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="42.6"/>
                    <measurement group_id="O2" value="7.68" spread="30.5"/>
                    <measurement group_id="O3" value="14.5" spread="46.9"/>
                    <measurement group_id="O4" value="7.92" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Steady State Concentration (Cmin,ss) for PK Population (All Subjects)</title>
        <description>Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK Population - Subjects with values for Cmin,ss</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Steady State Concentration (Cmin,ss) for PK Population (All Subjects)</title>
          <description>Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state</description>
          <population>PK Population - Subjects with values for Cmin,ss</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Pharmacokinetic parameters which could not be determined were identified by “not calculated (NC)”.</measurement>
                    <measurement group_id="O2" value="NA">Pharmacokinetic parameters which could not be determined were identified by “not calculated (NC)”.</measurement>
                    <measurement group_id="O3" value="NA">Pharmacokinetic parameters which could not be determined were identified by “not calculated (NC)”.</measurement>
                    <measurement group_id="O4" value="0.478" spread="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Steady State Concentration (Cmin,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state</description>
        <time_frame>27 days</time_frame>
        <population>PK Population excluding subjects with reported emesis - Subjects with values for Cmin,ss excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Steady State Concentration (Cmin,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state</description>
          <population>PK Population excluding subjects with reported emesis - Subjects with values for Cmin,ss excluding subjects with reported emesis</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Pharmacokinetic parameters which could not be determined were identified by “not calculated (NC)”.</measurement>
                    <measurement group_id="O2" value="NA">Pharmacokinetic parameters which could not be determined were identified by “not calculated (NC)”.</measurement>
                    <measurement group_id="O3" value="0.403" spread="102"/>
                    <measurement group_id="O4" value="0.609" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (All Subjects)</title>
        <description>CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration</description>
        <time_frame>27 days</time_frame>
        <population>PK Population - Subjects with values for CL/F,ss</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (All Subjects)</title>
          <description>CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration</description>
          <population>PK Population - Subjects with values for CL/F,ss</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1007" spread="29.7"/>
                    <measurement group_id="O2" value="833" spread="21.5"/>
                    <measurement group_id="O3" value="1310" spread="113"/>
                    <measurement group_id="O4" value="1228" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration</description>
        <time_frame>27 days</time_frame>
        <population>PK Population excluding subjects with reported emesis - Subjects with values for CL/F,ss excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration</description>
          <population>PK Population excluding subjects with reported emesis - Subjects with values for CL/F,ss excluding subjects with reported emesis</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="942" spread="19.6"/>
                    <measurement group_id="O2" value="839" spread="22.6"/>
                    <measurement group_id="O3" value="1008" spread="34.6"/>
                    <measurement group_id="O4" value="911" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (All Subjects)</title>
        <description>Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration</description>
        <time_frame>27 days</time_frame>
        <population>PK Population - Subjects with values for Vz/F,ss</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (All Subjects)</title>
          <description>Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration</description>
          <population>PK Population - Subjects with values for Vz/F,ss</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1167" spread="50.3"/>
                    <measurement group_id="O2" value="545" spread="40.6"/>
                    <measurement group_id="O3" value="1671" spread="135"/>
                    <measurement group_id="O4" value="897" spread="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
        <description>Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration</description>
        <time_frame>27 days</time_frame>
        <population>PK Population excluding subjects with reported emesis - Subjects with values for Vz/F,ss excluding subjects with reported emesis</population>
        <group_list>
          <group group_id="O1">
            <title>0.375 mg q.d.ER</title>
            <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O2">
            <title>0.125 mg t.i.d. IR</title>
            <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg q.d. ER</title>
            <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg t.i.d. IR</title>
            <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (Excluding Subjects Due to Emesis)</title>
          <description>Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration</description>
          <population>PK Population excluding subjects with reported emesis - Subjects with values for Vz/F,ss excluding subjects with reported emesis</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1092" spread="47.0"/>
                    <measurement group_id="O2" value="547" spread="43.2"/>
                    <measurement group_id="O3" value="1211" spread="37.8"/>
                    <measurement group_id="O4" value="625" spread="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>27 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.375 mg q.d.ER</title>
          <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
        </group>
        <group group_id="E2">
          <title>0.75 mg q.d. ER Up-titration</title>
          <description>0.75mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
        </group>
        <group group_id="E3">
          <title>1.5 mg q.d. ER</title>
          <description>1.5mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
        </group>
        <group group_id="E4">
          <title>0.75 mg q.d. ER Down-titration</title>
          <description>0.75mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
        </group>
        <group group_id="E5">
          <title>0.375 mg q.d.ER Down-titration</title>
          <description>0.375mg once daily (q.d.) of oral extended release (ER) tablet of pramipexole</description>
        </group>
        <group group_id="E6">
          <title>0.125 mg t.i.d. IR</title>
          <description>0.125mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
        </group>
        <group group_id="E7">
          <title>0.5 mg t.i.d. IR</title>
          <description>0.5mg thrice daily (t.i.d) of immediate release (IR) tablet of pramipexole</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

